Abstract: Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

Abstract: Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

Abstract: Described herein is the use of the optic nerve sheath (ONS) response to alterations in cerebrospinal fluid (CSF) pressure for predicting the risk of developing Visual Impairment and Intracranial Pressure (VIIP) syndrome in a subject.

Abstract: Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

Abstract: Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

Abstract: Described herein is the use of CSF or a CSF-like agent for increasing or promoting glymphatic system clearance in the optic nerve and/or retina for the treatment and/or prevention of retinal diseases, such as age-related macular degeneration, retinal vasculitis and commotio retinae. Also described herein is the use of a therapeutic agent for increasing or promoting glymphatic system clearance in the optic nerve and/or retina for the treatment and/or prevention of retinal diseases. The application further provides adjusted methods for the treatment and/or prevention of glaucoma.

Abstract: Described herein is the use of the optic nerve sheath (ONS) response to alterations in cerebrospinal fluid (CSF) pressure for predicting the risk of developing Visual Impairment and Intracranial Pressure (VIIP) syndrome in a subject.

Abstract: Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.